1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia
OC-3 is a potentially best-in-class PARP1 inhibitor for cancers that [...]
